As an organisation committed to driving change in caring for patients with diabetes and other chronic diseases, we have a responsibility to make Diversity, Equity, Inclusion & Belonging (DEIB) part of everything we do -- from developing our products to building and supporting our workforce.

Our commitment to DEIB is in keeping with the Novo Nordisk Way, which calls upon us to do all we can for the patients and communities we serve, including our own Novo Nordisk employees, some of whom are also patients and caregivers.

To innovate, we must be diverse. To enable diversity and thrive, we must have equity. To activate diversity and equity, we must be inclusive. To unlock our potential, we need belonging.

Our commitment to ensure diverse representation in our clinical trials is a key priority of our patient-centred business approach. We have worked diligently to proactively include sites and Investigators in our trials that engage with diverse patient populations, while raising awareness of the opportunities for clinical trial partnership and participation. With a deliberate focus on developing and improving upon our patient-facing materials and resources, and leveraging patient insights, we continuously improve upon our trial design and operational strategies.

We will continue to reinforce a culture of diversity, equity, inclusion and belonging in clinical trials, expanding and evolving our areas of focus to identify and address barriers to clinical trial participation, including access, mistrust and health disparities – staying focused on and dedicated to our patients, providers and communities.

At Novo Nordisk Canada, Employee Resource Groups (ERGs) drive our efforts to foster a sense of belonging and build a more diverse, equitable, and inclusive workplace.

Open to all, these groups enhance the work experience and professional development of many of our employees, and ultimately help us to retain and recruit a more diverse workforce to better serve patients and communities.